Evidence map›Paper›PMID 19738917›Full record

ArticleFrontiers in molecular neuroscience2009

Glycine and glycine receptor signalling in non-neuronal cells.

Jimmy Van den Eynden, Sheen Saheb Ali, Nikki Horwood, Sofie Carmans, Bert Brône, Niels Hellings, Paul Steels, Robert J Harvey, Jean-Michel Rigo

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06959251 (A Randomized, Placebo-controlled Clinical Trial Evaluating the Efficacy and Safety of Glycine and Magnesium+Thiamine Supplements, Alone or Combined, Administered for 6 Months to Patients With Primary Ciliary Dyskinesia), which is not on this map. Cited by 55 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06959251 narecruitingnot on this mapstarted 2025, after this paper: background citation

A Randomized, Placebo-controlled Clinical Trial Evaluating the Efficacy and Safety of Glycine and Magnesium+Thiamine Supplements, Alone or Combined, Administered for 6 Months to Patients With Primary Ciliary Dyskinesia

TypeinterventionalSponsorInstituto Nacional de Enfermedades RespiratoriasRan2025 to 2028Enrolled60ConditionsPrimary Ciliary DyskinesiaArmsGlycine, Magnesium+thiamine, Placebo
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Effects of glycine on metabolic syndrome components: a review.Journal of endocrinological investigation · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jimmy Van den EyndenInstitute of Biomedical Research, Hasselt University and transnationale Universiteit Limburg Diepenbeek, Belgium.
Sheen Saheb Ali
Nikki Horwood
Sofie Carmans
Bert Brône
Niels Hellings
Paul Steels
Robert J Harvey
Jean-Michel Rigo
Hasselt University · BE

Funding

Medical Research Council G0500833Medical Research Council G0500833(74778)Medical Research Council G0601585Medical Research Council G0601585(79887)
6 · The paper itself

Abstract

Glycine is an inhibitory neurotransmitter acting mainly in the caudal part of the central nervous system. Besides this neurotransmitter function, glycine has cytoprotective and modulatory effects in different non-neuronal cell types. Modulatory effects were mainly described in immune cells, endothelial cells and macroglial cells, where glycine modulates proliferation, differentiation, migration and cytokine production. Activation of glycine receptors (GlyRs) causes membrane potential changes that in turn modulate calcium flux and downstream effects in these cells. Cytoprotective effects were mainly described in renal cells, hepatocytes and endothelial cells, where glycine protects cells from ischemic cell death. In these cell types, glycine has been suggested to stabilize porous defects that develop in the plasma membranes of ischemic cells, leading to leakage of macromolecules and subsequent cell death. Although there is some evidence linking these effects to the activation of GlyRs, they seem to operate in an entirely different mode from classical neuronal subtypes.

Indexed as

cytoprotectionendothelial cellsgliaglycine receptorhepatocytesimmune cellsrenal cells

Identifiers

PMID19738917
PMCPMC2737430
OpenAlexW2166028744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.